Martin Barrett

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Andrew Davies, Francesco Merli, Biljana Mihaljević et al. · The Lancet Haematology · 2017 · 112 citations

Lymphoid Neoplasia, Medicine, Follicular Lymphoma +5

Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study

Andrew Davies, Francesco Merli, Biljana Mihaljević et al. · The Lancet Oncology · 2014 · 111 citations

Lymphoid Neoplasia, Medicine, Randomised Phase 3 +7

Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson et al. · Blood · 2023 · 24 citations

Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Max S. Topp, Monica Tani, Michael Dickinson et al. · Blood · 2022 · 23 citations

The Parasite of Oral Endamebiasis, Endameba gingivalis (Gros)

Allen J. Smith, Martin Barrett · Journal of Parasitology · 1915 · 21 citations · Full text

Allergy, Medicine, Oral Cavity +12